HK1022700A1 - Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained - Google Patents

Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained

Info

Publication number
HK1022700A1
HK1022700A1 HK00100944A HK00100944A HK1022700A1 HK 1022700 A1 HK1022700 A1 HK 1022700A1 HK 00100944 A HK00100944 A HK 00100944A HK 00100944 A HK00100944 A HK 00100944A HK 1022700 A1 HK1022700 A1 HK 1022700A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
crystals
virus
protease domain
complex
Prior art date
Application number
HK00100944A
Other languages
English (en)
Inventor
Joseph L Kim
Kurt A Morgenstern
Chao Lin
Ted Fox
John A Thomson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of HK1022700A1 publication Critical patent/HK1022700A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK00100944A 1996-09-12 2000-02-17 Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained HK1022700A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
PCT/US1997/016182 WO1998011134A1 (en) 1996-09-12 1997-09-12 Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained

Publications (1)

Publication Number Publication Date
HK1022700A1 true HK1022700A1 (en) 2000-08-18

Family

ID=26699520

Family Applications (2)

Application Number Title Priority Date Filing Date
HK00100944A HK1022700A1 (en) 1996-09-12 2000-02-17 Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
HK01108615A HK1038573A1 (en) 1996-09-12 2000-02-17 Method to identify agents active against hcv by using the structure coordinates of hepatitis c virus protease

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK01108615A HK1038573A1 (en) 1996-09-12 2000-02-17 Method to identify agents active against hcv by using the structure coordinates of hepatitis c virus protease

Country Status (13)

Country Link
US (2) US6153579A (de)
EP (1) EP0935609B1 (de)
JP (1) JP2001501602A (de)
AT (3) ATE216400T1 (de)
AU (1) AU736857B2 (de)
CA (1) CA2264964A1 (de)
DE (3) DE69723485T2 (de)
DK (1) DK0935609T3 (de)
ES (2) ES2202228T3 (de)
HK (2) HK1022700A1 (de)
IL (1) IL128826A0 (de)
PT (2) PT1118619E (de)
WO (1) WO1998011134A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979327B (en) 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
JP2002534084A (ja) 1999-01-08 2002-10-15 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスｎｓ３プロテアーゼの修飾形
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
EP1222459A4 (de) 1999-10-14 2003-01-22 Bristol Myers Squibb Co Kristallographische struktur der bindungsstelle des androgenen rezeptors
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1334179A2 (de) 2000-11-14 2003-08-13 Bristol-Myers Squibb Company Menschliches serpin aus lymphoidzellen lsi-01 sekretiert
EP1567642A4 (de) 2001-04-03 2006-02-08 Bristol Myers Squibb Co Neue cysteinprotease der calpain-superfamilie codierendes polynukleotid, can-12, und varianten davon
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
AU2004285019B9 (en) 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP2392590A3 (de) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis-C-Virusvarianten
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
KR20080112303A (ko) * 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
CA2679426A1 (en) 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
KR20090115970A (ko) 2007-02-27 2009-11-10 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 그를 포함하는 제약 조성물
JP5443360B2 (ja) 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
WO2012118982A2 (en) 2011-03-02 2012-09-07 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Also Published As

Publication number Publication date
PT1118619E (pt) 2003-11-28
HK1038573A1 (en) 2002-03-22
ATE216400T1 (de) 2002-05-15
EP0935609B1 (de) 2002-04-17
WO1998011134A1 (en) 1998-03-19
AU4414597A (en) 1998-04-02
US6153579A (en) 2000-11-28
DE69723485D1 (de) 2003-08-14
DE69736995D1 (de) 2007-01-04
PT935609E (pt) 2002-09-30
EP0935609A1 (de) 1999-08-18
US6303287B1 (en) 2001-10-16
DE69723485T2 (de) 2004-05-27
DE69712085T2 (de) 2002-11-28
DE69736995T2 (de) 2007-09-20
CA2264964A1 (en) 1998-03-19
DE69712085D1 (de) 2002-05-23
ES2202228T3 (es) 2004-04-01
ES2175462T3 (es) 2002-11-16
ATE346088T1 (de) 2006-12-15
IL128826A0 (en) 2000-01-31
ATE244729T1 (de) 2003-07-15
AU736857B2 (en) 2001-08-02
DK0935609T3 (da) 2002-07-22
JP2001501602A (ja) 2001-02-06

Similar Documents

Publication Publication Date Title
HK1022700A1 (en) Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
BG103392A (en) Serine protease inhibitors, in particular of hepatitis with virus ns3 protease
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
AU1416099A (en) Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
FI941199A0 (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
ATE500323T1 (de) Subtilisin-variante
ES2165269A1 (es) Derivados de alfa-cetoamidas.
ATE171710T1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
DE68917837T2 (de) Peptid-Verbindungen.
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE69106141T2 (de) Non-a non-b sequenzen.
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
SE9604439D0 (sv) New receptor
IT1270941B (it) Peptidi di hcv e loro usi.
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060912